SIU 2017: Presence of Only Clinical Stage T2c Is Not Sufficient to be Classified as High Risk Prostate Cancer
Lisbon, Portugal (UroToday.com) According to the EAU guidelines cT2c stage is classified as high risk prostate cancer. However, most patients presenting only with cT2c disease and no other negative prognostic factors, have better outcomes after local therapy. The aim of the study was to assess prognostic factors of biochemical recurrence (BR) in a subgroup of prostate cancer (PC) patients only with cT2c stage.
SIU 2017: GA-PSMA-PET/CT VS. Choline-PET/CT in Malignant Prostate Cancer - A Systematic Review
Lisbon, Portugal (UroToday.com) The role of Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) has increasingly become more prominent in helping diagnose recurrent prostate cancer and advanced prostate cancer. The role of PSMA as a radio tracer appears to be surpassing that of choline tracers in prominent centers. The authors report a comparison, based on current data, between the use of PSMA-PET/CT scans and Choline PET/CT scans.
SIU 2017: Comparison of 68Ga-PSMA-PETCT with Multiparametric MRI for Staging High Risk Prostate Cancer
Lisbon, Portugal (UroToday.com) Glu-NH-CO-NH-Lys(Ahx) Ga-68(HBED-CC))) (Ga-68 PSMA 11) is a positron emission tomography (PET) imaging agent that is increasingly being evaluated in prostate cancer. It is used for staging of prostate cancer, localizing recurrence in patients with biochemical relapse and finding metastases in patients with castration resistant prostate cancer. In this study the authors attempted to compare Ga-68 PSMA 11 PET/CT with multiparametric MRI for the staging of high risk prostate cancer.
SIU 2017: Comparison of Multiparametric and Biparametric MRI Cognitive Targeted First Round Prostate Biopsy for Patients with a PSA Level under 10 Ng/Ml
Lisbon, Portugal (UroToday.com) This study attempted to determine the efficacy of cognitive targeted prostate biopsy using bi-parametric magnetic resonance imaging (b-MRI) for patients with a PSA level less than 10 ng/ml.
SIU 2017: Impact of Canadian Task Force on Preventative Health Care Recommendation Against PSA Screening on Radical Prostatectomy Results
Lisbon, Portugal (UroToday.com) Following a similar recommendation by its American counterpart, the Canadian Task Force on the Preventative Health Care (CTFPHC) produced a guideline recommending against standard screening for prostate cancer (PCa) with prostate-specific antigen (PSA) in 2014. Like in the US, there has been concern among Canadian urologists that decreased PSA use in primary care might result in diagnosis of higher risk disease and adverse outcomes.
SIU 2017: Novel Classification of Gleason 7 Prostate Cancer According to the Discrepancy between Biopsy and Final Gleason Score after Radical Prostatectomy
Lisbon, Portugal (UroToday.com) This study, presented by Dr. Cho, evaluated the impact of pathological upgrading of Gleason score 7 prostate cancer on the risk of biochemical recurrence after radical prostatectomy (RP).
SIU 2017: Local Treatment for Metastatic Prostate Cancer
Lisbon, Portugal (UroToday.com) Dr. Tilki presented today on the status of local treatment for metastatic prostate cancer (mPCa), an increasingly exciting field with potential for lots of change in the near future.
First, she focused on the oligometastatic PCa disease space. Initially described as an intermediate state between localized disease and widespread systematic metastases, the definition now varies by the number and location of metastases, with no consistency in the literature. There are numerous ongoing clinical trials, which have yet to report data, but the definitions vary across the board – anywhere from 3-10 lymph nodes, +/- visceral mets, or not-specified.